ExSight Ventures
Venture capitalNew York · Pre-Seed–Series B · 4 people tracked
Find your way into ExSight Ventures
258 people in our graph share verified history with the ExSight Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
ExSight Ventures invests in early-stage companies developing breakthrough technologies to aid, diagnose, and treat people affected by vision diseases. The firm leverages deep ophthalmology domain expertise—led by two retinal surgeons—as an advantage over generalist investors, treating its focused specialization as a form of validation for a company's technology. It emphasizes capital efficiency, investing predominantly in technology development at the pre-seed through Series B stages. The firm argues that diversification is best achieved across focused managers rather than across holdings, and points to macro trends such as an aging population, rising diabetes, and a growing global middle class as drivers of demand for eye care innovation.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's websiteWhat they invest in
from 16 of 22 portfolio companiesBiotech ×11Healthtech ×9Medical Devices ×7AI & Machine Learning ×3Media & Entertainment ×2Advanced Manufacturing ×1Consumer ×1Data & Infrastructure ×1
HQs:United States×10United Kingdom×1Japan×1
Investments · 22 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 22022 · 22019 · 12017 · 17 dated
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
Co-investorsInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsHatteras Venture PartnersSolasta VenturesAccess BiotechnologyBios PartnersCorrelation VenturesFemHealth Ventures+2 more
HealthtechIrvine, US
JAMES TAYLOR(Executive Officer)IRVING ROBERT ARMSTRONG(Executive Officer)ROBERT SHIMIZU(Executive Officer)NARESH MANDAVA(Director)
BoardAKITERU FURUKAWA(Director)CLAUDE BENEDICT(Director)
Co-investorsInFocus Capital Partners, LLC
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.
BiotechHealthtechSan Diego, US
Arthur T Suckow(Executive Officer)inArthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyRA CapitalJanus Henderson Investors
Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.
A Japanese manufacturer and seller of billiard equipment, including cues, tips, and chalk, serving players and retailers worldwide through overseas distributors across 25+ countries.
Advanced ManufacturingConsumerHiroshima, JP
Masato Hiraoka(Chairman)Kazumi Kuwahara(President)
Reinventing the eye exam with binocular OCT-based diagnostic technology.
Torrance, US
Richard Castro(Executive Officer)Alexander Walsh(Executive Officer, Director)Patrick Welsh(Director)Patrick Walsh(Director)Paul Updike(Executive Officer)
Horizon Surgical Systems develops surgical robotics for ophthalmic procedures, with a focus on improving cataract surgery.
AI & Machine LearningHealthtechMedical DevicesRobotics
Springer is an academic and scientific publisher with a portfolio of over 2,700 journals and more than 220,000 books, serving researchers, authors, readers, and institutions worldwide.
Media & Entertainment
Co-investorsChanzo Capital
LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia.
BiotechHardwareHealthtechMedical DevicesIrvine, US
Ramgopal Rao(Founder & Chief Executive Officer)
BoardAkiteru Furukawa(Director)Michael Colaco(Director)Shivbir Grewal(Director)
Co-investorsLightstone Ventures
Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesReading, GB
Prof. Francesca Cordeiro(Founder, Director & Chief Executive Officer)Prof. M. Francesca Cordeiro(Founder & CEO)MARIA FRANCESCA CORDEIRO(Director)
BoardNATALIE PANKOVA(Director)KARL DAVID KEEGAN(Director)STEPHEN ROY PAGE(Director)
Co-investorsAnglia Capital GroupInBC Investment Corp.Zinc
Co-investorsClarendon Fund Managers Ltd.Visionary Ventures
First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.
BiotechAnn Arbor, US
Sean Ainsworth(Executive Officer, Director)
BoardTerry Cross(Director)Kenneth Kousky(Director)Cam Gallagher(Director)George Lasezkay(Director)
Co-investorsBoston Harbor AngelsGREAT LAKES BAY VENTURESanten Pharmaceutical
BiotechSpringfield, US
Ramanath Bhandari(Executive Officer)Jeff Olson(Director)
BoardRam Palanki(Director)
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesLongitude CapitalTachyon VenturesThe Column Group
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect BioventuresExSight
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningData & Infrastructure
Art Abal(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalCaladanEarl Grey CapitalParadigmSCB 10X+7 more
Exits · 2
IPOs and acquisitions across the tracked portfolioDTx Pharmaacq. by NovartisRetroSense Therapeuticsacq. by Allergan
Portfolio news
latest coverage across their companiesEnvision · tipranks.com · Aug 20, 2026
Trefoil Therapeutics · hatterasvp.com · Jan 9, 2026
RevOpsis Therapeutics · finsmes.com · Sep 16, 2025
NOVAI · globenewswire.com · Mar 11, 2025
Frequently asked questions
- How many investments has ExSight Ventures made?
- ExSight Ventures has 19 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does ExSight Ventures invest at?
- ExSight Ventures invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does ExSight Ventures focus on?
- ExSight Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is ExSight Ventures located?
- ExSight Ventures is headquartered in New York.
- Who does ExSight Ventures co-invest with?
- ExSight Ventures most often shares deals with Visionary Ventures, First Spark Ventures, Llc, Lightstone Ventures, among 23 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund that provides early-stage capital and operational support to Pennsylvania life science companies working on drug discovery, diagnostics, devices, and healthcare IT solutions.
Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
The Vertical Group is a venture capital firm focused on medical technology and biotechnology. Independent since 1988, it is the successor to the venture capital division of F. Eberstadt & Co.